#

Novo Nordisk

: 109
Eli Lilly Raises Forecast Thanks to the Success of Its Weight-Loss Drugs / Photo: Tada Image / Shutterstock.com
News·
Lilly raised its revenue forecast. This eased fears that the weight-loss boom is on the decline
Novo Nordisk shares fell after the company reported disappointing sales results for its weight-loss drug / Photo: Shutterstock.com / Kittyfly
News·
Weak sales of Wegovy overshadowed Novo's "clearly less-than-impressive" forecast revision
Elon Musks SpaceX will release its first quarterly report this week following its IPO / Photo: X/SpaceX
News·
SpaceX's Earnings Report, the Job Market, and Big Pharma: What Investors Can Expect This Week
The failure of Novo Nordisks drug trials sent its stock tumbling 10% / Photo: JHVEPhoto / Shutterstock
News·
Novo Nordisk shares plummeted 10% after a heart drug trial failed
Novo Nordisk shareholders have succeeded in securing the launch of a judicial investigation into the results of testing for the drug CagriSema / Photo: gguy / Shutterstock
News·
Novo Will Sue Investors Over the Results of a Study on a Weight-Loss Drug
Profits at British pharmaceutical giant AstraZeneca exceeded analysts expectations last quarter. Photo: Konektus Photo/Shutterstock
News·
Oncology drugs helped boost AstraZeneca's profits by 21%. Will the company expand its portfolio?
Novo Nordisk Accuses Eli Lilly of Unfair Advertising / Photo: oleschwander / Shutterstock
News·
Novo has filed a lawsuit against its competitor, Eli Lilly, over advertisements for weight-loss drugs
Shares of Zealand Pharma plummeted as much as 25% after new data on an experimental weight loss medicine raised concerns over its side effects / Photo: MAXSHOT.PL / Shutterstock
Small Caps·
Small weight loss drugmaker Zealand sinks as new safety data spooks investors
Sales of Wegovy in tablets beat forecasts / Photo: JHVEPhoto / Shutterstock
News·
Sales of Novo Nordisk's obesity pill double expectations. Shares soared
AI solutions provider for collecting and analyzing large sets of disparate data (Big Data) Palantir is poised to surpass Nvidia in long-term sales growth / Photo: rblfmr/Shutterstock.com
News·
US employment, Palantir and Novo earnings: what investors need to know this week
Elon Musk is pushing the idea of accelerating SpaceXs inclusion in the S&P 500 after its IPO, which is set to be the largest in history / Photo: Alessia Pierdomenico/Shutterstock.com
News·
S&P goes after SpaceX, Uzbekistan fund to offer discount: the main thing about the IPO by Ma. 3
Hemab is developing therapies for blood coagulation disorders such as Glanzmann thrombasthenia and Von Willebrand Disease, according to its filings / Photo: Hemab Therapeutics
Small Caps·
+1
·
Hemab IPO: Novo-backed blood disorder biotech debuts on the Nasdaq
Load more